Eli Lilly Snags Long-Awaited Alzheimer's Drug Approval, Rivaling Biogen, EisaiInvestors Business Daily • 07/02/24
Lilly's Kisunla™ (donanemab-azbt) Approved by the FDA for the Treatment of Early Symptomatic Alzheimer's DiseasePRNewsWire • 07/02/24
Want Decades of Passive Income? 2 Top Dividend Stocks to Buy Now and Hold Forever.The Motley Fool • 07/01/24
Eli Lilly Is Teaming Up With OpenAI. Here Are 3 Things Smart Investors Should Know.The Motley Fool • 06/29/24